Rocket Lab's $1.9B Stock Sale: Smart Move or Overpriced?

Rocket Lab (RKLB) announced on Sept. 15 that it has fully funded its pending acquisition of satellite operator Iridium Communications (IRDM) through a $1.94 billion at-the-market stock sale. The company sold approximately 29.3 million new shares at an average price of about $66 each. This move replaces a $3.6 billion bridge loan from Deutsche Bank and Wells Fargo that was arranged in late June.

The stock sale covers about two-thirds of the $2.9 billion cash portion of the deal, with the remainder coming from Rocket Lab's existing cash and short-term investments. Iridium shareholders will receive $27 per share in cash, plus Rocket Lab stock at a ratio between 0.24 and 0.40 shares per Iridium share, depending on Rocket Lab's stock price at closing.

The acquisition values Iridium at about $8 billion including debt. Iridium brings its own $1.8 billion term loan, which will remain in place after the deal closes. The merger is expected to complete in mid-2027, pending regulatory approvals and an Iridium shareholder vote on Sept. 24.

Rocket Lab's decision to sell stock instead of borrowing was driven by its unprofitable status. The company posted a net loss of $49.3 million in the second quarter, though this was narrower than the $66.4 million loss a year earlier. A $3.6 billion loan due within a year would have required refinancing at uncertain rates, adding significant financial risk.

The stock sale resulted in dilution of about 5% based on 598 million shares outstanding as of Aug. 5. When including preferred shares that convert to common, dilution is closer to 4.5%. However, the total dilution could reach 12% when accounting for the additional shares to be issued to Iridium shareholders at closing.

The choice to sell stock rather than take on debt is a double-edged sword for Rocket Lab investors. On one hand, avoiding a $3.6 billion loan due within a year removes a significant financial overhang and strengthens the balance sheet. This is particularly important for a company that is not yet profitable and operates in a capital-intensive industry. The move reduces the risk of a liquidity crunch and allows Rocket Lab to focus on integrating Iridium without the immediate pressure of debt repayment.

On the other hand, the dilution is real. Existing shareholders now own a smaller piece of the company. The 29.3 million new shares represent about 5% dilution, and the total share count could grow by up to 12% once the deal closes. This means that future earnings, when they come, will be spread across more shares, potentially limiting upside for current holders.

The timing of the sale also raises questions. Rocket Lab sold shares at an average of $66, which is below the current price of around $69 and less than half the 52-week high of $151. While the company raised a substantial amount, it did so at a discount to recent highs, which may indicate that management saw limited windows to raise capital at better prices.

Looking ahead, the acquisition of Iridium is expected to transform Rocket Lab's business. Iridium generated about $872 million in revenue in 2025 with a 57% OEBITDA margin, which will significantly boost Rocket Lab's top line. However, the combined company will still carry Iridium's $1.8 billion debt, and integration risks remain. The market's reaction has been muted, with RKLB stock up 8.24% on the news, suggesting investors are weighing the benefits of a stronger balance sheet against the dilution and the premium valuation.

At the current price of around $69, Rocket Lab has a market capitalization above $40 billion, which is more than 40 times its annualized revenue. This is a rich valuation for a company that is still unprofitable, and it leaves little room for error. The financing decision may have been prudent, but it doesn't change the fact that the stock is expensive.